In our hands, CLL cell lines were relatively insensitive and seemed to be protected by high BCL‐2 expression, as combination therapy of CC‐115 with the BCL‐2 inhibitor venetoclax showed synergy in three investigated CLL cell lines (Fig. S2). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.